A case with sarcomatoid hepatocellular carcinoma and literature review

Sarcomatoid hepatocellular carcinoma (SHC) is a relatively rare subtype of liver cancer reported in 1.8–2.0% of surgically resected cases. Previous studies have found that SHC was more likely to occur in patients who received repeated anticancer therapies, but the underlying mechanism has not been exactly illustrated. We report a case of a 62-year-old man with SHC. With the initial implication of abscess suspected liver mass by radiological exams (enhanced Computed Tomography and liver Magnetic Resonance Imaging), the patient underwent a laparoscopic pus debridement and biopsy. The diagnosis of SHC was considered by pathologists. After a short recovery, a second radical resection of the liver tumor and hepatic hilar lymph node dissection were conducted. Postoperative pathology revealed a tumor-free incisal margin and negative lymph node. The recovery of the patient was uneventful. When confronting an occasional liver mass with previous Hepatitis B virus infection, SHC should be included for a candidate diagnosis. If diagnosis is confirmed, high biological malignancy and poor survival should be expected. Surgery is still a main option to treat SHC.

Sarcomatoid cancer; Hepatocellular carcinoma; Sarcomatoid hepatocellular carcinoma; Hepatapostema; Hepatophyma liver abscess; Liver mass

[1] Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. Gastroenterology Clinics of North America. 2017; 46: 365–391.

[2] Wu L, Tsilimigras DI, Farooq A, Hyer JM, Merath K, Paredes AZ, et al. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: a population-based analysis. Cancer. 2019; 125: 3767–3775.

[3] Morisue R, Kojima M, Suzuki T, Nakatsura T, Ojima H, Watanabe R, et al. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepa-tocellular carcinoma: clinicopathologic, transcriptomic and immunologic analyses. International Journal of Cancer. 2021; 149: 546–560.

[4] Zhou C, Zhang X, Zhou K, Hou Y, Chen F, Zhang X, et al. Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma. Annals of Translational Medicine. 2022; 10: 394.

[5] Ji W, Xing Y, Ma J, Zhao Z, Xu H, Zheng S, et al. Primary liver sarcomatoid carcinoma: a case series and literature review. Journal of Hepatocellular Carcinoma. 2021; 8: 1117–1127.

[6] Liao S, Su T, Jeng Y, Liang P, Chen D, Chen C, et al. Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma. Hepatology. 2019; 69: 209–221.

[7] Lv T, Hu H, Regmi P, Liu F, Li F. Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology. 2022; 148: 1685–1696.

[8] Giannis D, Morsy S, Geropoulos G, Esagian SM, Sioutas GS, Moris D. The epidemiology, staging and outcomes of sarcomatoid hepatocellular carcinoma: a SEER population analysis. In Vivo. 2021; 35: 393–399.

[9] Yoshida N, Midorikawa Y, Kajiwara T, Yoshida N, Nakayama H, Sugitani M, et al. Hepatocellular carcinoma with sarcomatoid change without anticancer therapies. Case Reports in Gastroenterology. 2013; 7: 169–174.

[10] Yokomizo J, Cho A, Yamamoto H, Nagata M, Takiguchi N, Kainuma O, et al. Sarcomatous hepatocellular carcinoma without previous anticancer therapy. Journal of Hepato-Biliary-Pancreatic Surgery. 2007; 14: 324–327.

[11] Inagaki Y, Sugimoto K, Shiraki K, Yoshizawa N, Tameda M, Ogura S, et al. Sarcomatous hepatocellular carcinoma with remittent fever. Internal Medicine. 2012; 51: 3025–3029.

[12] Shin HP, Jeon JW, Park JJ, Cha JM, Joo KR, Lee JI, et al. A case of leukemoid reaction in a patient with sarcomatous hepatocellular carcinoma. The Korean Journal of Hepatology. 2011; 17: 226–228.

[13] Gu K, Kim YK, Min JH, Ha SY, Jeong WK. Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging. Abdominal Radiology. 2017; 42: 1424–1433.

[14] Shi D, Ma L, Zhao D, Chang J, Shao C, Qi S, et al. Imaging and clinical features of primary hepatic sarcomatous carcinoma. Cancer Imaging. 2018; 18: 36.

[15] Koo HR, Park M, Kim M, Lim JS, Yu J, Jin H, et al. Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. Journal of Computer Assisted Tomography. 2008; 32: 745–749.

[16] Zhang H, Chai S, Chen L, Wang Y, Cheng Y, Fang Q, et al. MRI features of hepatic sarcomatoid carcinoma different from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Frontiers in Oncology. 2021; 11: 611738.

[17] Ijichi H, Shirabe K, Taketomi A, Yoshizumi T, Ikegami T, Mano Y, et al. Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma. Hepatology Research. 2013; 43: 481–487.

[18] Lu J, Xiong X, Li F, Ye H, Lin Y, Zhou R, et al. Prognostic significance of sarcomatous change in patients with hepatocellular carcinoma after surgical resection. Annals of Surgical Oncology. 2015; 22: S1048–S1056.

[19] Luo C, Xin H, Yin D, Zhao T, Hu Z, Zhou Z, et al. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma. Aging. 2021; 13: 15126–15138.

[20] Zhu S, Li H, Yuan Z, Liu W, Yang Q, Cheng Y, et al. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: a case report. World Journal of Gastrointestinal Oncology. 2020; 12: 1209–1215.

[21] Ge D, Luo Z, Mao R, Zhao H, Lv X, Zhao J, et al. Development and validation of a nomogram-based prognostic evaluation model for sarcomatoid hepatocellular carcinoma. Advances in Therapy. 2020; 37: 3185–3205.